Alnylam Pharma (ALNY) Misses Q3 EPS by 15c

October 28, 2021 8:13 AM EDT

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

Alnylam Pharma (NASDAQ: ALNY) reported Q3 EPS of ($1.72), $0.15 worse than the analyst estimate of ($1.57). Revenue for the quarter came in at $187.6 million versus the consensus estimate of $218.54 million.

2021 Financial Guidance

2021 Financial Guidance

Full year 2021 financial guidance is reiterated and consists of the following:

Combined net product revenues for
ONPATTRO, GIVLAARI and OXLUMO

$640 million - $665 million

Net revenues from collaborations and royalties

$150 million - $200 million

GAAP R&D and SG&A expenses

$1,335 million - $1,455 million

Non-GAAP R&D and SG&A expenses*

$1,175 million - $1,275 million

For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Earnings, Guidance

Related Entities

Earnings